SCHEMBL2726979

SCHEMBL2726979

O=C(C(c1ccccc1)(c1ccccc1)c1ccccc1)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 10/20 0.56
CYP1A2 P05177 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
MAPT P10636 1/20 0.46
KMT2A Q03164 1/20 0.46
CYP2C19 P33261 2/20 0.44
HIF1A Q16665 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
PTPN1 P18031 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10538155 0.86 KIF11 (0.46) KCNN4CYP1A2NPSR1KMT2AHDAC3
SCHEMBL29934990 0.86 KCNN4 (0.71) KCNN4NPSR1KMT2AKCNE1KCNQ1
SCHEMBL409257 0.85 KCNN4 (0.54) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL10727252 0.85 KCNN4 (0.48) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL3523419 0.83 KCNN4 (0.58) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL45520 0.82 CYP1A2 (0.56) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL7880822 0.80 CYP1A2 (0.54) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL10909643 0.80 CYP1A2 (0.54) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL10403424 0.80 CYP1A2 (0.54) KCNN4CYP1A2NPSR1MAPTKMT2A
SCHEMBL11522471 0.80 CYP1A2 (0.54) KCNN4CYP1A2NPSR1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029501-B2 Method for making macrocycles RIGEL PHARMACEUTICALS, INC. (US) 2015-05-12 US claimed
US-20130217874-A1 METHOD FOR MAKING MACROCYCLES RIGEL PHARMACEUTICALS, INC. (US) 2013-08-22 US claimed
WO-2012061408-A2 METHOD FOR MAKING MACROCYCLES RIGEL PHARMACEUTICALS. INC. (US) 2012-05-10 WO claimed
CN-112680089-B Long-acting antistatic coating and application and product thereof 安徽辅朗光学材料有限公司 2022-07-05 CN disclosed
US-4039413-A OXYGEN-FREE, UV OR VISIBLE LIGHT, ORGANIC PEROXIDE, ACRYLIC POLYMERSON ROHM GMBH (DT) 1977-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217874-A1 METHOD FOR MAKING MACROCYCLES EZR, SQLE, CBR3 KCNN4 3004/4885CYP1A2 260/4885NPSR1 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.